Overactive Bladder Treatment Market to Witness Robust Growth in North America & Asia Pacific

 

Overactive bladder (OAB) is not a disease, it is a problem with bladder function that causes the sudden need to urinate. Diabetes, an enlarged prostate, and ageing are the major risk factors. Treatments such as pelvic floor muscle exercises, medication, and nerve stimulation can reduce or eliminate symptoms. Thus, with the increasing incidence of overactive bladder, worldwide, the demand for Overactive Bladder Treatment is also increasing. In October 2020, Zydus Cadila received final approval from the United States Food and Drug Administration (FDA) to market Solifenacin Succinate tablets, for the treatment of overactive bladder. The company received approval to market Solifenacin Succinate tablets, in the strengths of 5 mg and 10 mg.

This in turn is expected to accelerate the growth of the Overactive Bladder Treatment market. Frequent urination and urine leakage are the main symptoms of overactive bladder. Frequent urination is common in such patients. Overactive bladder is commonly diagnosed by tests such as urodynamic testing, cystoscopy, bladder scan, or urine culture. Overactive bladder describes a combination of symptoms that can include a frequent urge to urinate and waking up at night to urinate. According to the Urology Health Foundation, As many as 30 percent of men and 40 percent of women in the United States live with the symptoms overactive bladder. This in turn is expected to increase the demand for overactive bladder treatment in the region.

For instance, in January 2021, the FDA approved vibegron (Gemtesa; Sumitovant Biopharma) 75 mg tablets. Vibegron is now commercially available in the United States for the treatment of adult patients with overactive bladder (OAB with symptoms of urge urinary incontinence (UUI), urgency, and urinary frequency, according to Urovant Sciences, the developer of the β3‐adrenoreceptor agonist. Therefore, the Overactive Bladder Treatment market is expected to witness substantial growth in North America region. According to the National Association for Incontinence 2020, around 25 million adults in the U.S. suffer from some form of urinary incontinence, among them 75 to 80% are women.

The Asia Pacific is also expected to witness robust growth in the overactive bladder treatment market, due to the increasing prevalence of bladder over-activity, increasing awareness about overactive bladder treatments, the increasing healthcare expenditure, and the growing geriatric population. Thus, there is an increasing demand for overactive bladder treatment in the region. Medications help relieve symptoms of overactive bladder. These drugs include: Tolterodine (Detrol) Oxybutynin, which can be taken as a pill (Ditropan XL) or used as a skin patch.

https://www.coherentmarketinsights.com/ongoing-insight/overactive-bladder-treatment-market-2007